CDF
New price gets Clovis’ PARP inhibitor on the CDF
George Underwood
CDF, Clovis, Clovis Oncology, ovarian cancer, PARP inhibitor, Rubraca
0 Comment
Market Access/ Oncology/ Views & Analysis/ Views & Analysis/ Views and analysis
NICE’s track record in cancer drugs: the impact of the CDF and interim funding
Leela Barham
cancer, Cancer Drugs Fund, CDF, HTA, NICE, NICE numbers at 20
0 Comment
Articles/ Cancer/ Pharma Market Access/ UK & Europe/ Views and analysis
Pharma’s new ‘sensible pricing’ behind cancer drug approvals, says NICE
Brexit/ Debates/ Debates & Insight/ Market Access/ News/ Pharma Market Access/ Webinars/ Webinars in home page/ Webinars On demand
02/11/2016
Finding a cure: Getting the best Brexit deal for Britain’s life sciences
Adam Jeffery
ABPI, Brexit, cancer, CASMI, CDF, debate, Dorrell, exclusive, McFarlane, NICE, quintilesIMS, Report, webinar
1 Comment
Articles/ Cancer/ Pharma Market Access/ UK & Europe/ Views and analysis
A novel UK approach to cancer access: yes, no, or maybe?
Richard Staines
Cancer Drugs Fund, CDF, market access, NHS, patients, pharma, Real World Evidence, RWE
0 Comment
Experts discuss the implications of the new, reinvigorated Cancer Drugs Fund, for pharma and patients.
Articles/ Cancer/ Healthcare/ UK & Europe/ Views and analysis
England’s ‘world-first’ cancer database – can it deliver on its promise?
Andrew McConaghie
ABPI, cancer, cancer database, CDF, Public Health England, SACT
0 Comment
The world’s first national database of cancer treatment outcomes has been launched in England.
Articles/ Cancer/ Digital and Social Media/ UK & Europe/ Views and analysis
What doctors say about changes to the Cancer Drugs Fund
Marco Ricci
cancer, Cancer Drugs Fund, CDF, HCP, new CDF, NHS, NICE, social media
0 Comment
Assessing HCPs’ social media comments about the new approach to cancer drug funding.
NICE says no to liver cancer drug Nexavar
Andrew McConaghie
Bayer, CDF, Liver cancer, Nexavar, NICE
0 Comment
Liver cancer treatment latest earmarked for removal from CDF